| Browse All

BriaCell Therapeutics Corp. (BCTX)

Healthcare | Biotechnology | West Vancouver, Canada | NasdaqCM
4.43 USD +0.11 (2.546%) ⇧ (April 17, 2026, 4 p.m. EDT)
After hours: 4.51 +0.08 (1.734%) ⇧ (April 17, 2026, 7:51 p.m. EDT)

Short-term: ★☆☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆
Hot Take | April 11, 2026, 2:44 p.m. EDT

BriaCell Therapeutics Corp. (BCTX) presents a highly volatile and uncertain investment profile. The recent price history shows significant fluctuations, with the stock trading below its 50-day average and experiencing a sharp decline over the last few weeks. The stock's negative forward PE and trailing EPS suggest poor profitability, and the high beta indicates it is more sensitive to market movements than the broader market. The recent news headlines highlight both positive developments, such as the addition of a license and a credit lifeline, and negative events like a stock plunge following a $30 million offering. These mixed signals suggest a lack of clear momentum. Additionally, the absence of dividends indicates that this stock is not suitable for income-focused investors. Given the lack of a clear upward trend, the high volatility, and the negative fundamentals, this stock is not a favorable short-term or long-term investment at this time.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
AutoETS ✓0.154242
AutoARIMA0.154247
AutoTheta0.163296
MSTL0.195268

Forecast horizon: 45 days | Selected: AutoETS

Forecast Reliability
Score 80%
H-stat 0.69
Ljung-Box p 0.000
Jarque-Bera p 0.666
Excess Kurtosis -0.44
Attribute Value
Sector Healthcare
Market Cap 32,119,656
Forward P/E -11.36
Beta 1.63
Website https://briacell.com

Info Dump

Attribute Value
52 Week Change -0.8942721
Address1 Bellevue Centre
Address2 Suite 300 235 -15th Street
All Time High 1,563.518
All Time Low 3.5
Ask 5.64
Ask Size 2
Average Daily Volume10 Day 133,650
Average Daily Volume3 Month 264,775
Average Volume 264,775
Average Volume10Days 133,650
Beta 1.626
Bid 3.22
Bid Size 2
Book Value 4.264
City West Vancouver
Compensation As Of Epoch Date 1,767,139,200
Country Canada
Crypto Tradeable 0
Currency USD
Current Price 4.43
Current Ratio 10.102
Custom Price Alert Confidence HIGH
Date Short Interest 1,774,915,200
Day High 4.54
Day Low 4.36
Display Name BriaCell Therapeutics
Dividend Date 1,577,923,200
Earnings Timestamp End 1,750,104,000
Earnings Timestamp Start 1,749,758,400
Ebitda -30,630,110
Ebitda Margins 0.0
Enterprise To Ebitda -0.049
Enterprise Value 1,513,398
Eps Forward -0.39
Eps Trailing Twelve Months -14.42
Esg Populated 0
Exchange NCM
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fax 604 921 1898
Fifty Day Average 4.152
Fifty Day Average Change 0.27799988
Fifty Day Average Change Percent 0.066955656
Fifty Two Week Change Percent -89.42721
Fifty Two Week High 98.2
Fifty Two Week High Change -93.77
Fifty Two Week High Change Percent -0.954888
Fifty Two Week Low 3.6
Fifty Two Week Low Change 0.8299999
Fifty Two Week Low Change Percent 0.23055553
Fifty Two Week Range 3.6 - 98.2
Financial Currency USD
First Trade Date Milliseconds 1,331,731,800,000
Float Shares 6,410,301
Forward Eps -0.39
Forward P E -11.358974
Free Cashflow -20,493,214
Full Exchange Name NasdaqCM
Gmt Off Set Milliseconds -14,400,000
Gross Margins 0.0
Has Pre Post Market Data 1
Held Percent Insiders 0.0060799997
Held Percent Institutions 0.01153
Implied Shares Outstanding 7,250,487
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Ipo Expected Date 2,021-02-24
Is Earnings Date Estimate 1
Language en-US
Last Fiscal Year End 1,753,920,000
Last Split Date 1,756,080,000
Last Split Factor 1:10
Long Business Summary BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp., has a collaboration with MSK Accelerator to accelerate the clinical development of Bria-OTS+ for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers. The company is headquartered in West Vancouver, Canada.
Long Name BriaCell Therapeutics Corp.
Market us_market
Market Cap 32,119,656
Market State CLOSED
Max Age 86,400
Message Board Id finmb_262266102
Most Recent Quarter 1,769,817,600
Net Income To Common -29,637,656
Next Fiscal Year End 1,785,456,000
Non Diluted Market Cap 32,226,432
Open 4.36
Operating Cashflow -30,967,316
Operating Margins 0.0
Payout Ratio 0.0
Phone 604 921 1810
Post Market Change 0.07680035
Post Market Change Percent 1.7336422
Post Market Price 4.5068
Post Market Time 1,776,469,874
Previous Close 4.32
Price Hint 4
Price To Book 1.0389305
Profit Margins 0.0
Quick Ratio 9.387
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key none
Region US
Regular Market Change 0.11
Regular Market Change Percent 2.54629
Regular Market Day High 4.54
Regular Market Day Low 4.36
Regular Market Day Range 4.36 - 4.54
Regular Market Open 4.36
Regular Market Previous Close 4.32
Regular Market Price 4.43
Regular Market Time 1,776,456,000
Regular Market Volume 113,716
Return On Assets -0.89438003
Return On Equity -1.7920799
Sand P52 Week Change 0.38150132
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Shares Outstanding 7,250,487
Shares Percent Shares Out 0.039
Shares Short 282,815
Shares Short Previous Month Date 1,772,150,400
Shares Short Prior Month 103,944
Short Name BriaCell Therapeutics Corp.
Short Percent Of Float 0.039
Short Ratio 1.19
Source Interval 15
State BC
Symbol BCTX
Total Cash 29,903,628
Total Cash Per Share 4.124
Total Debt 0
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -14.42
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 8.2787
Two Hundred Day Average Change -3.8487
Two Hundred Day Average Change Percent -0.46489185
Type Disp Equity
Volume 113,716
Website https://briacell.com
Zip V7T 2X1